Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Greenwald

Showing results (151-160 of 195) with videos related to

Pageof 20
Sort By:
Oncogene|April 13, 2005
Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression riskKarsten Schulmann, Anca Sterian, Agnes Berki, et al.
Oncogene|February 2, 2006
Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesisS Wang, M Zhan, J Yin, et al.
Gastroenterology|January 1, 1997
A transforming growth factor beta 1 receptor type II mutation in ulcerative colitis-associated neoplasmsR F Souza, J Lei, J Yin, et al.
Water Research X|August 10, 2021
Tools for interpretation of wastewater SARS-CoV-2 temporal and spatial trends demonstrated with data collected in the San Francisco Bay AreaHannah D Greenwald, Lauren C Kennedy, Adrian Hinkle, et al.
Plos One|April 3, 2008
Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical featuresFumiaki Sato, Zhe Jin, Karsten Schulmann, et al.
Journal of the National Cancer Institute|November 18, 2000
Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinomaK Kawakami, J Brabender, R V Lord, et al.
Human Cell|September 1, 1996
Alterations of transforming growth factor-beta 1 receptor type II occur in ulcerative colitis-associated carcinomas, sporadic colorectal neoplasms, and esophageal carcinomas, but not in gastric neoplasmsR F Souza, L Garrigue-Antar, J Lei, et al.
The American Journal of Gastroenterology|August 14, 2024
Validation of an Epigenetic Prognostic Assay to Accurately Risk-Stratify Patients With Barrett EsophagusSarah E Laun, Lisa Kann, Jerome Braun, et al.
Gastrointestinal Endoscopy|May 25, 2002
EUS-guided fine needle aspiration of the liver: indications, yield, and safety based on an international survey of 167 casesJorgen tenBerge, Brenda J Hoffman, Robert H Hawes, et al.
JAMA Network Open|April 21, 2023
Association of Radiotherapy Duration With Clinical Outcomes in Patients With Esophageal Cancer Treated in NRG Oncology Trials: A Secondary Analysis of NRG Oncology Randomized Clinical TrialsChristopher L Hallemeier, Jennifer Moughan, Michael G Haddock, et al.
Pageof 20

Showing results (151-160 of 195) with videos related to

Sort By:
Pageof 20
Oncogene|April 13, 2005
Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression riskKarsten Schulmann, Anca Sterian, Agnes Berki, et al.
Oncogene|February 2, 2006
Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesisS Wang, M Zhan, J Yin, et al.
Gastroenterology|January 1, 1997
A transforming growth factor beta 1 receptor type II mutation in ulcerative colitis-associated neoplasmsR F Souza, J Lei, J Yin, et al.
Water Research X|August 10, 2021
Tools for interpretation of wastewater SARS-CoV-2 temporal and spatial trends demonstrated with data collected in the San Francisco Bay AreaHannah D Greenwald, Lauren C Kennedy, Adrian Hinkle, et al.
Plos One|April 3, 2008
Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical featuresFumiaki Sato, Zhe Jin, Karsten Schulmann, et al.
Journal of the National Cancer Institute|November 18, 2000
Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinomaK Kawakami, J Brabender, R V Lord, et al.
Human Cell|September 1, 1996
Alterations of transforming growth factor-beta 1 receptor type II occur in ulcerative colitis-associated carcinomas, sporadic colorectal neoplasms, and esophageal carcinomas, but not in gastric neoplasmsR F Souza, L Garrigue-Antar, J Lei, et al.
The American Journal of Gastroenterology|August 14, 2024
Validation of an Epigenetic Prognostic Assay to Accurately Risk-Stratify Patients With Barrett EsophagusSarah E Laun, Lisa Kann, Jerome Braun, et al.
Gastrointestinal Endoscopy|May 25, 2002
EUS-guided fine needle aspiration of the liver: indications, yield, and safety based on an international survey of 167 casesJorgen tenBerge, Brenda J Hoffman, Robert H Hawes, et al.
JAMA Network Open|April 21, 2023
Association of Radiotherapy Duration With Clinical Outcomes in Patients With Esophageal Cancer Treated in NRG Oncology Trials: A Secondary Analysis of NRG Oncology Randomized Clinical TrialsChristopher L Hallemeier, Jennifer Moughan, Michael G Haddock, et al.
Pageof 20